Annovis Bio, Inc. · NYSE:ANVS
Annovis Bio — Corporate Update (October 2021)
12 slides from Annovis Bio's corporate update, Oct 5, 2021
Slide 1: New Parkinson's Efficacy Data
New Parkinson’s Efficacy Data Symbol: ANVS (NYSE American) October 5, 2021
Slide 2: Forward-Looking Statements
FORWARD - LOOKING STATEMENTS Statements in this presentation contain “forward - looking statements” that are subject to substantial risks and uncertainties. Forward - looking statements contained in this presentation may be identified by the use of words such as “anticipate,” “expect,” “believe,” “w
Slide 3: Corporate Updates
3 Quarterly Calls CORPORATE UPDATES Appointments PD Data • Starting next year, we will conduct quarterly conference calls • We are actively in the process of hiring a Chief Medical Officer • General overview of n ew positive Parkinson’s disease top - line efficacy data
Slide 4: Two Phase 2 Clinical Trials
AD Trial PD Trial Therapeutic Area Early to Moderate AD and PD Phase 2 Patients 14 14 + 40 Design Double - Blind, Placebo - Controlled, Biomarker Study Endpoints Reversal of Toxic Cascade Exploratory Efficacy TWO PHASE 2 CLINICAL TRIALS 4
Slide 5: Improved Cognition in AD Patients – ADAS-Cog11
IMPROVED COGNITION IN AD PATIENTS – ADAS - Cog11 D ata from 14 AD patients 5 From baseline to 25 days in the ANVS401 - treated group, ADAS - Cog11 improved by 4.4 points, a statistically significant improvement of 30%. Compared to placebo at 25 days the t reated group is 3.3 points better than the p
Slide 6: Efficacy Trend in PD Patients – MDS-UPDRS Test
EFFICACY TREND IN PD PATIENTS – MDS - UPDRS TEST Data from 14 PD patients - Total UPDRS 6 ANVS401 - treated group showed trends of improvement in UPDRS test total score compared to placebo -14.00% -12.00% -10.00% -8.00% -6.00% -4.00% -2.00% 0.00% UPDRS % Total Score Placebo ANVS401 Improvement
Slide 7: Improved Speed and Accuracy in AD and PD Patients – WAIS Coding Test
IMPROVED SPEED AND ACCURACY IN AD AND PD PATIENTS WAIS CODING TEST D ata from 14 AD and 14 PD patients The WAIS coding test measures speed in movement and thinking. Treated AD patients show a statistically - significant 23% improvement from baseline. Treated PD patients show a statistically - signif
Slide 8: Complete 54 PD Patient Clinical Trial
PD Therapeutic Area Early to Moderate PD Phase 2 Patients 54 Design Double - Blind, Placebo - Controlled, Biomarker Study Dose 0, 5, 10, 20, 40, 80 mg/day Endpoints Reversal of Toxic Cascade Exploratory Efficacy COMPLETE 54 PD PATIENT CLINICAL TRIAL 8
Slide 9: Efficacy in PD Patients – WAIS Coding Test
EFFICACY IN 54 PD PATIENTS – WAIS CODING TEST 9 Across the dose response the WAIS coding test showed improvements in speed of movement and coordination Improvement
Slide 10: Efficacy in PD Patients – MDS-UPDRS Test
EFFICACY IN 54 PD PATIENTS – MDS - UPDRS Test -18.00% -16.00% -14.00% -12.00% -10.00% -8.00% -6.00% -4.00% -2.00% 0.00% UPDRS % Total Score Placebo 5mg 10mg 20mg 40mg 80mg Improvement The MDS - UPDRS test showed the most improvements at 10 and 20 mg once per day * * 10
Slide 11: Summary and Next Steps
SUMMARY AND NEXT STEPS ▪ Annovis has a novel approach to stop AD and PD ▪ ANVS401 shows improvements in Phase 2a clinical trials: - Cognition in AD patients - Motor function in PD patients - WAIS coding in AD and PD patients ▪ T his is the first double - blind, placebo - controlled study that shows
Slide 12: Thank You, Questions?
THANK YOU QUESTIONS? Symbol: ANVS (NYSE American)